Swiss Nordic Bio 2017

Filter profiles by…

Clear
Clear
Biotech and Pharmaceuticals
Investments
Business Services
Ownership
Other
Clear
Clear
Clear

148 results, 148 profiles in total

Investment/funding offered Investment/funding offered Companies looking for international investors. We have international investors with several companies on Nasdaq coming to 37 ºC Life Science Technology Conference & Exhibition 6th-7th June 2017 Stavanger Forum in Norway. We would like to invite Swiss and Nordic companies. https://37degreescelsius.net/ More…
Investment/funding requested Investment/funding requested Investors looking for deal flow. We will have exciting realy stage companies and potential co-investors with Nasdaq coming to 37 ºC Life Science Technology Conference & Exhibition 6th-7th June 2017 Stavanger Forum in Norway. We would like to invite Swiss and Nordic investors. https://37degreescelsius.net/ More…
Partner request / distributor needed Partner request / distributor needed International partners for commercialisation and co-investment. We will have companies and potential co-investors with Nasdaq coming to 37 ºC Life Science Technology Conference & Exhibition 6th-7th June 2017 Stavanger Forum in Norway. That are looking for partners for commercialisation of technology. And that are looking for international... More…
Partners Request (Research) Partners Request (Research) Acute Kidney Injuries. Please describe your co-operation profile according to the example headings mentioned below. Find examples of good co-operation profiles on www.b2match.eu/ssbbs2012/participants/14 or www.b2match.eu/go4cleantech/pages/profiles More…
Investment/funding requested Investment/funding requested Bringing central-lab quality diagnostics to point-of-care. ABACUS shortens the diagnosis time for respiratory, urinary tract, and gastrointestinal infections to less than 30 minutes from the standard 2-5 days. These diseases are primary reasons to enter primary care and more than half of the population are infected annually, causing direct and indirect... More…
Investment/funding requested Investment/funding requested New class of antibiotics + Novel Mode of action + Clinical stage lead candidate for new indication. AntibioTx is one of a few companies on a global scale to be advancing a potentially new class of antibiotics with a novel mechanism of action in the clinic. The nature of our lead candidates – ATx201 and ATx301 – enables a short path to the market with high probability of success while the... More…
Outlicensing offered Outlicensing offered Novel anti-coagulant aptamer drug candidate without bleeding disorder. Aptahem i currently working on its lead candidate Apta 1 in a pre-clinical saftey/tox 1 stage. In benchmark tests with market leading drugs Apta 1 not only shows a exceptional inhibition of coagulation but it also do this without any increased bleeding effect despite more than 10-fold... More…
Outlicensing offered Outlicensing offered Industry Spin-Out. Astrazeneca offers investors access to off strategy innovation and a possibility to utilize AZ BioVentureHub (www.azbioventurehub.com) for incorporattion. Assets are typically divested in return for limited equity. Current asset pool contains preclinical and clinical assets as well as MedTech... More…
Investment/funding requested Investment/funding requested Phase IIa opportunity. Athera, a clinical stage biotech company, is focused on developing targeted anti-inflammatory biotherapeutics and companion diagnostics for the prevention and treatment of immunovascular diseases. Athera was founded based on innovations made at Karolinska Institutet. Main Investors are... More…
Partners Request (Research) Partners Request (Research) BC Platforms is looking for R&D partners for their latest business program called BC|RQUEST. We are looking for R&D partners to our latest business program called BC|RQUEST. In practise we are looking and searching biotech and pharma companies to partner in our knowledge business development that involved technical development and conceptual development. BC is building a network of... More…
Investment/funding requested Investment/funding requested Invest into next generation proteomics. More…
Investment/funding requested Investment/funding requested BioLingus - oral delivery of peptides, proteins and vaccines. BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immune-therapies. It is a cutting-edge and mature solution for oral formulations not only for peptides, but also small molecules, novel protein... More…
Investment/funding requested Investment/funding requested Biopolymer Products of Sweden AB. More…
Investment/funding requested Investment/funding requested Investment for growth and genetic data platform. We are a clinical genetic testing company based in Helsinki, San Francisco and Dubai. We provide high quality NGS Panels for all 14 different medical specialties and comprehensive clinical Exome testing. We work with customers like Boston Children’s, Cincinnati Children’s, University of British... More…
Investment/funding requested Investment/funding requested C-class shares. Next-generation POCT platform for tracking infectious diseases BluSense technology enables the accurate diagnosis of dengue and zika using a single drop of blood. Combining biomarker quantification with portability, affordability and ease of use, BluSense point-of-care products are designed... More…
Investment/funding requested Investment/funding requested Blood analysis technology for global clinical use. More…
Investment/funding requested Investment/funding requested West Sweden's business opportunities. Our goal is to present concrete business and investments opportunities in West Sweden. We are representing West Sweden's investment portfolio within biotech, medtech, eHealth, bioinformatics,etc. More…
Partners Request (Research) Partners Request (Research) Co-development and R&D collaboration with West Sweden's companies and organsiations. Our goal is to present concrete business and investments opportunities in West Sweden. We are representing West Sweden's investment portfolio within biotech, medtech, eHealth, bioinformatics,etc. More…
Partner offer / supplier needed Partner offer / supplier needed Business Sweden in Switzerland - SSBBS project coordinator. Business Sweden's office in Zurich belongs to the regional office in Vienna, which also covers Austria, Slovenia and Croatia, and handles requests for Serbia, Montenegro, Macedonia, Bosnia & Herzegovina, Kosovo and Albania. Together, the team consists of seven employees. We have over the years... More…
Investment/funding offered Investment/funding offered PE investments for a better life. Private Equity Investments in lean start-up enterprises mainly in Europe to create values for a better life. Investing directly or together with partners in a variety of enterprises preferably in Med Tech with focus on tele health. More…
Investment/funding requested Investment/funding requested Investment oppotunity in CardiNor AS. CardiNor AS is a newly established Norwegian biotech company to handle the commercialization of Secretoneurin (SN), a new biomarker for cardiovascular disease (CVD). The use of SN for CVD is based on research carried out at Akershus University Hospital, HUS, Oslo University Hospital and... More…
Partner request / distributor needed Partner request / distributor needed International distributor for Cellevates nanofiber based product line for 3D cell culture. Cellevate has since 2014 developed a product line for 3D cell culture based on nanofiber scaffolds (www.cellevate.com/products) that we currently sell primarily to academic research groups. We are now looking for an international distributor to help us reach a broader range of customers. More…
Partner request / distributor needed Partner request / distributor needed Nanofiber Scaffolds for 3D cell culturing. Cellevate has since 2014 developed a product line for 3D cell culture based on nanofiber scaffolds (www.cellevate.com/products) that we currently sell primarily to academic research groups. We are now looking for an international distributor to help us reach a broader range of customers. The... More…
Investment/funding requested Investment/funding requested ChromaCon AG Series A. ChromaCon AG is seeking a Series A financing in the range of CHF 4m to be closed towards the 2nd half of 2017. More…
Outlicensing offered Outlicensing offered Beta peptide library technology. More…
Partner for EUREKA/Eurostars collaboration wanted Partner for EUREKA/Eurostars collaboration wanted Screening of beta peptide libraries. ChromaCon has a patented technology for the fast construction of directed libraries. The molecules are metabollically stable beta-peptides and can be decorated with virtually any side-chain modification. Thus, prior knowledge about the drug target can be considered in the library design. The easy... More…
Partners for research cooperation needed Partners for research cooperation needed Screening of beta peptide libraries. ChromaCon has a patented technology for the fast construction of directed libraries. The molecules are metabollically stable beta-peptides and can be decorated with virtually any side-chain modification. Thus, prior knowledge about the drug target can be considered in the library design. The easy... More…
Investment/funding offered Investment/funding offered CILIQUE provides Angel Financing. More…
Investment/funding requested Investment/funding requested Investors to develop the market in Europe. Clean Lab is a provider of clean air cabinets and associated products. We have created Biological Safety Cabinets, with unique features, that enhances the quality of the work being carried out, worker satisfaction as well as lowering total cost of operation. Two factors have made this possible.... More…
Investment/funding requested Investment/funding requested Treatment of chronic cough associated with serious respiratory diseases. Conrig Pharma repositions drug molecules with attractive safety and efficacy profiles provide new treatments of serious illnesses. Initial focus will be on development of ST 015 for treatment of cough associated with seroius respiratory disorders and ST-016 or ST-018 for treatment of chronic... More…
Partners Request (Research) Partners Request (Research) Executive Search. Global Life Sciences Executive Search More…
Investment/funding offered Investment/funding offered Venture Capital offered. Creathor Venture manages funds of more than EUR 180 million (USD 240 mio) and currently has four Offices in Germany (near Frankfurt & Munich), in Zurich and in Stockholm. We invest anywhere from a few hundred thousand up to five million per case. More…
Partner for EUREKA/Eurostars collaboration wanted Partner for EUREKA/Eurostars collaboration wanted Research Center providing innovative solutions for Life Sciences and Diagnostics. CSEM is a private applied research and development center specializing in micro- and nanotechnology. One focus of our innovation activities is in micro-diagnostics, combining sensors, microfluidics, and overall integration and packaging. CSEM has a long and successful history of collaborations... More…
Partner offer / supplier needed Partner offer / supplier needed Offer: innovation development based on CSEM's nanotechnology- and microelectronics knowledge for life-science and medtech applications. CSEM is active in technology development from prototypes to small-series production and in technology transfer to industry in Switzerland and in Europe. With its basis in micro- and nanotechnologies and in micro-electronics CSEM develops solutions for a wide range of applications in life science... More…
Investment/funding requested Investment/funding requested Cura8 main focus. Cura8 are mainly interested in meeting investors and partners on distribution, manufacturing and pharmaceutical big data. More…
Investment/funding offered Investment/funding offered Cura8 main focus. Cura8 are mainly interested in talking to investors and partners in distribution, manufacturing and pharmaceutical big data. More…
Investment/funding requested Investment/funding requested Cytovation. Cytovation was founded in 2001 with Professor Bjerkvig and Professor Lønning as the key persons involved together with Innovest, representing Haukeland University Hospital and The University of Bergen. The purpose of setting up the company was to commercialize inventions made by the founders.... More…
Outlicensing offered Outlicensing offered T20K for multiple sclerosis. T20K is a novel, proprietary drug originating from the Medical University of Vienna. Cyxone had acquired the patent rights, is currently working towards gaining and IND and aim for phase I in 2017/2018. Cyxone is well founded through phase I and is seeking a pharma partner to accelerate the... More…
Partner offer / supplier needed Partner offer / supplier needed Danish Ministry of Foreign Affairs. As part of the Danish Ministry of Foreign Affairs, Invest in Denmark specializes in business solutions for foreign companies looking to set up business in Denmark. We focus on industries like Life Sciences and Cleantech where Denmark holds proven competitive global strengths. Add to those an... More…
Outlicensing offered Outlicensing offered Preclinical PET ligands and drug candidates for partnering and outlicensing. Focus on diagnosis of vulnerable plaque in arteries and therapy for orphan movement disorders.. Preclinical PET ligands and drug candidates for partnering and outlicensing PET-ligands: NET (noradrenaline transporter reuptake inhibitors): 11C-NS8880 and 18F-NS12137 Alpha7 nicotinic: 11C-NS14492, 18F-NS10743 and 18F-NS14490 18F-NS14490 with complete radiochemistry including stable... More…
Investment/funding offered Investment/funding offered Investments. Late seed / Round A investment for - Smart Data companies - Pharmaceutical companies - Diagnostics companies More…
Partners for research cooperation needed Partners for research cooperation needed Co-development partner. Diamyd Medical is manufacturing pharmaceutical grade GABA for use in clinical and preclinical studies focused on diabetes and autoimmune diseases. Additionally Diamyd Medical licenses certain rights for the use of GABA alone or in combination with other immunomodulatory agents in type 1 diabetes,... More…
Outlicensing offered Outlicensing offered Diamyd (rhGAD65 / alum) - Antigen Specific Immunotherapy for treating autoimmune diabetes. Diamyd is currently in phase II development for treating recently diagnosed type 1 diabetes and individuals at high risk for type 1 diabetes. Additional patient populations include prevalent type 1 diabetics and LADA. Value drivers: - Very high likelihood (98%) of positive biological effect... More…
Partner for EUREKA/Eurostars collaboration wanted Partner for EUREKA/Eurostars collaboration wanted Projects within diabetes or autoimmune diseases. Focus on islet-cell biology and immune tolerance. Diamyd Medicals assets are the diabetes vaccine Diamyd (rhGAD65; phase II), GABA (type 1 diabetes, type 2 diabetes, RA). Extensive experience from clinical studies in diabetes and large network of key opinion leaders. More…
Manufacturing offered Manufacturing offered Dottikon Exclusive Synthesis AG. DOTTIKON EXCLUSIVE SYNTHESIS AG manufactures exclusive active pharmaceutical ingredients (APIs), high-quality intermediates and performance chemicals for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is... More…
Manufacturing offered Manufacturing offered DOTTIKON EXCLUSIVE SYNTHESIS. DOTTIKON EXCLUSIVE SYNTHESIS, with its production site in Dottikon (Aargau, Switzerland), is specialized in hazardous chemical reactions. Its safety culture created over the last 100 years is utilized to innovatively use hazardous reactions, low-temperature and high-pressure chemistry as well as... More…
Investment/funding requested Investment/funding requested DEVELOPING NEW PRODUCTS FOR THE TREATMENT OF PAIN. - DESCRIPTION OF PROJECT Pain is an unmet medical need, many people experience pain and it’s a big problem both for the patient, their family and society. The US is in the midst of a prescription overdose epidemic resulting in extensive health care costs and suffering for abusers and their... More…
Investment/funding offered Investment/funding offered Venture Capital Growth Stage. Interested in Medtech & Digital Health opportunities in growth stage. We offer field expertise and focus on heling companies expand internationally. More…
Investment/funding requested Investment/funding requested Investment. I am representing a start-up project from EPFL and CHUV in Lausanne. We have patented a platform of surgical material (scaffolds and injectables) that can stimulate natural tissue regeneration in animal models. Our projects are currently funded by CTI. The aim is at the end of our CTI grants to... More…
Investment/funding offered Investment/funding offered Ergomed Plc. Co-Development in clinical trials. ERGOMED is one of the market leaders in co-development and can invest in broad co-development partnerships with clients where there is a mutual interest and expertise. Ergomed is one of the market leaders in “co-development” partnerships signing its first partnership agreement in 2006. The scope... More…
Partners Request (Research) Partners Request (Research) Support to transnational partnerships in innovation and technology. The Enterprise Europe Network (EEN) Switzerland is mandated by the Swiss State Secretariat for Education, Research and Innovation (SERI). The EEN supports Swiss SMEs in their international development efforts, by facilitating technology transfers, international partnerships and agreements, and... More…
Investment/funding offered Investment/funding offered Horizon 2020 SME Instrument. As of 1 January 2017 Swiss companies can benefit from the SME Instrument programme, from which they were excluded until now. The Horizon 2020 SME Instrument is a funding scheme dedicated to established, high growth, highly innovative, for-profit SMEs seizing European and global business... More…
Investment/funding requested Investment/funding requested FIDA – enabling biopharmaceuticals - same technology and assays from early discovery through postmarketing.. FIDA-Tech ApS is a start-up company offering products and services based on Flow Induced Dispersion Analysis, which is a patented, new, truly disruptive technology for identification and quantification of proteins and antibodies in the development and administration of biopharmaceuticals. The... More…
Investment/funding requested Investment/funding requested Final product testing and organisational development. More…
Investment/funding requested Investment/funding requested Finpro. Finpro helps Finnish SMEs go international, encourages foreign direct investment in Finland and promotes travel to Finland. Finpro is a public organization consisting of Export Finland, Visit Finland and Invest in Finland. Invest in Finland promotes foreign investments into Finland or Finnish... More…
Investment/funding requested Investment/funding requested Networking for Future Investment Round B. Forendo Pharma has had a successful financing history, since the foundation of the company in 2013. Our seed investment round in 2013 resulted in €3,5M from Novo Seeds, Karolinska Development and Finnvera. During Round A in 2014, we gained access to €12M, with both earlier and new investors,... More…
Outlicensing offered Outlicensing offered Licensing opportunity: Fispemifene, novel solution for unmet needs in male urological conditions. Fispemifene is a novel selective estrogen receptor modulator (SERM), with a unique tissue-specific pharmacological profile. It offers opportunities for the treatment of male urological conditions. TARGET PATIENTS: Secondary Hypogonadism Hypogonadism is a state of testosterone deficiency that has... More…
Outlicensing offered Outlicensing offered New CNS molecules acting on the Gaba receptor.. Gabather is developing new small-molecule drug candidates for treatment of anxiety, depression, pain and memory enhancement via the Gaba receptor pathway. More…
Investment/funding requested Investment/funding requested Investment opportunity in Genetic Analysis AS. Genetic Analysis (GA) is a molecular invitro diagnostic company with mapping of microbiota as its core competence. GA was established in 2008 and is developing innovative solutions for improved patient treatment in rapidly growing markets. GA has launched the GA-map™ Dysbiosis Test, the first... More…
Partners Request (Research) Partners Request (Research) Data analysis for sequencing and other complex biological measurements. Genevia offers flexible services for analyzing biological measurements (such as sequencing, proteomics and microarrays) to companies working in life sciences internationally. Our current clients include a variety of research groups and companies in pharmaceutical development, medtech and... More…
Investment/funding requested Investment/funding requested GlucoSet is seeking 4M€ to finance a medical device pivotal clinical study. DESCRIPTION OF PROJECT: ICU patients get stress hyperglycemia. Intensive insulin therapy significantly reduces length of stay and complication risk (eg infection, kidney failure). However, without reliable continuous glucose monitoring, intensive insulin therapy is not safe or effective because... More…
Investment/funding offered Investment/funding offered HBM Partners - Leading International Investor in Healthcare Companies. More…
Investment/funding offered Investment/funding offered Co-investors and new investment opportunities. We are one of the largest Scandinavian VC -players with EUR 400m balance sheet. We are interested in finding new investment opportunites as well as co-Investors to our portfolio companies. Our investment region is primarily Scandinavia. More…
Investment/funding requested Investment/funding requested InfiCure Bio seeks investment or funding to finish validation of the preclinical model and to attract a body of costumers. InfiCure Bio has a preclinical mouse model which spontaneously develops fibrosis in several organs including liver, skin and kidney. The model will be offered to pharmaceutical companies our biotech companies for effect tests of new anti-inflammatory and/or anti-fibrotic drugs. We seek... More…
Outlicensing offered Outlicensing offered InfiCure Bio offers to perform effect tests of anti-inflammatory/anti-fibrotic drugs in our unique preclinical fibrosis model. InfiCure Bio has developed a unique preclinical mouse model, the N-IF mouse, for testing of anti-inflammatory/anti-fibrotic drugs. Development of fibrosis in the model is very similar to that seen in many human conditions as it is spontaneous, preceded by a state of chronic inflammation and... More…
Investment/funding requested Investment/funding requested Inflamalps is developing INF101, a molecule for the treatment of inflammatory diseases of the eye: uveitis and dry eye. Inflamalps is looking to raise CHF8 million to move INF101 through to preclinical development up to phase Ib in uveitis and Sjogren's associated dry eye indications. INF101 acting via a novel mechanism of action is able to inhibit Th17 differentiation and was shown to effectively prevent the... More…
Investment/funding offered Investment/funding offered Innovation Centre Denmark Munich is your gateway to European markets with high concentration of state-of-the-art industry and R&D.. We help you connect with high tech companies, researchers, and institutions of higher education in order to assess your business case, develop and adapt your technology, or find collaboration partners. More…
Investment/funding offered Investment/funding offered facilitating international projects and partner collaboration incl. Eurostars. Innovation Centre Denmark works to establish closer cooperation between Danish and German innovation actors in order to strengthen Danish research, education, innovation and policy development. Germany is Europe's largest economy and Denmark’s largest export market by far and the possibilities... More…
Investment/funding requested Investment/funding requested Invest in Skåne. Invest in Skåne is the Official Inward Investment agency of Southern Sweden, which free of charge help foreign companies with activities in the region. Southern Sweden is part of Medicon Valley, one of the strongest medical technology, pharmaceutical and biotechnological growth centres in Europe,... More…
Investment/funding requested Investment/funding requested Official Inward Investment Agency of Southern Sweden. Invest in Skåne is the Official Inward Investment agency of southern Sweden, which free of charge help foreign companies with activities in the region. Southern Sweden is part of Medicon Valley, one of the strongest medical technology, pharmaceutical and biotechnological growth centres in Europe,... More…
Outlicensing offered Outlicensing offered More than 80 projects in pipeline of drug development projects. Skåne has more than 80 projects in pipeline of drug development projects within oncology, neurology, metabolic disorders and inflammation More…
Investment/funding requested Investment/funding requested Invest Stockholm. Invest Stockholm is the official investment promotion agency of Stockholm. Stockholm is widely recognized as one of the most innovative regions in the world – let us help you discover why. Based on your needs we can help you get connected to the ecosystem of top-notch companies, universities and... More…
Investment/funding requested Investment/funding requested Business Development Manager. Business development services When you’re considering making a direct investment, getting the required information is crucial. Our business development services lead to better decisions. Information and benchmarking services We offer clients benchmarking analysis using a number of qualitative... More…
Partners Request (Research) Partners Request (Research) preclinical and early clinical development of anti-lymphoma compounds. Our preclinical and clinical team has a strong expertise on novel anti-lymphoma compounds. We're pleased to discuss novel collaboration on these topics. More…
Investment/funding offered Investment/funding offered Collaboration in accelerating early-stage innovation. Johnson & Johnson Innovation, LLC focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies one-stop access... More…
Partners for research cooperation needed Partners for research cooperation needed Collaboration in accelerating early-stage innovation. Johnson & Johnson Innovation, LLC focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies one-stop access... More…
Partners for research cooperation needed Partners for research cooperation needed Contract Research Organisation, specialized in oncology. Junvik Clinical Development Consulting is a CRO based in Malmö, southern Sweden. We provide feasibility, monitoring, submissions, and project management in Scandinavia, as well as medical writing, general ad-hoc support and advice for biotechs. JCDC provides expertise within clinical development... More…
Investment/funding offered Investment/funding offered Offering engineering services to start-up companies as an investment. You have finally come to the point where you need professionally engineered machines or test equipment and you don't want to hire a large team of engineers? konplan (ISO 13485 certified Swiss Medical Engineering SME company) might help. We are a team of about 40 skilled and experienced... More…
Investment/funding requested Investment/funding requested Funding for market expansion of our EU approved medical foods for cancer and bariatric surgery pasients. We are currently selling this product in Norway, Greece, China and Hongkong. We have signed a distribution contract with an Argentina company. We are looking funding for financing the market growth into other markets Europe, South America and Asia. Building upon the Norwegian heritage of a... More…
Investment/funding requested Investment/funding requested Blood glucose lowing and cholesterol reducing functional food for diabetics. The products are patented and bear EFSA approved health claims. We are looking for funding in order to realise our market launch in Europe and Asia. Meanwhile, we are also looking for distributors with strong sales network in the pharmacy channel and trained sale team in Europe and Asia. We... More…
Investment/funding requested Investment/funding requested Juvenile Idiopathic Arthritis - possible orphan drug designation. Juvenile Idiopathic Arthritis (JIA) is a group of inflammatory articular disorders with onset before the age of 16 years and of at least six weeks duration and is for some of the patients considered especially problematic with low treatment success rates and poor prognosis. Progression to erosive... More…
Outlicensing offered Outlicensing offered Rheumatoid Arthritis - novel target for treatment. Current treatments of severe rheumatoid arthritis include a biological drug targeting the pro-inflammatory cytokine TNFα. These so called “blockbuster drugs” did in fact change the treatment of rheumatoid arthritis dramatically. But, a large group of patients do not respond to these drugs at all,... More…
Investment/funding requested Investment/funding requested Invest in Lunaphore. (1) Lunaphores Series A round of CHF 5M to be closed Q1-2017 Funds will allow Lunaphore platform CE-Marked. Half of the round has already been raised. Looking for one lead investor to complement the second half. (2) Lunaphore Series B round of CHF 10M to be closed in 2018 We are interested in... More…
Partners for research cooperation needed Partners for research cooperation needed Co-development partners. We are eager to collaborate with partners that are looking for a tissue diagnostic technology. We are the only tissue diagnostic technology with the following features: • Fast Fluidic Exchange: Reagent delivery/cleaning within 1s offering tremendous control over reactions. • Reproducible... More…
Investment/funding requested Investment/funding requested Investment requested. M-V Arterica is currently looking for investments More…
Partner for EUREKA/Eurostars collaboration wanted Partner for EUREKA/Eurostars collaboration wanted Eurostars. M-V Arterica is looking for a partner to cooperate with More…
Investment/funding requested Investment/funding requested Making O-15 H2O practically available for clinical use. MedTrace help doctors worldwide diagnose heart patients in PET centers better and more efficiently by offering an automated solution for production and infusion of O-15 H2O as a tracer for myocardial perfusion exams. We are raising our series A round looking for a syndication of investors with... More…
Investment/funding requested Investment/funding requested Series B financing round to develop preclinical assets as well as technology. More…
Investment/funding offered Investment/funding offered Merck Ventures. Merck Ventures is the strategic, corporate venture capital arm of Merck. Our mandate is to invest in innovative technologies and products with the potential to significantly impact Merck’s core business areas. From our headquarters in Amsterdam and offices in the US and Israel we invest globally... More…
Partner for EUREKA/Eurostars collaboration wanted Partner for EUREKA/Eurostars collaboration wanted Development. We are looking for different kind of research and product development cooperation which require DNA/RNA synthesis or analysis parts. Field of interest are in the development of novel - genotyping methods - disease specific sequencing pannels - CRISPR/Cas assays / kit development The project... More…
Investment/funding offered Investment/funding offered Early-stage funding & successful exit strategies. Please describe your co-operation profile according to the example headings mentioned below. Monitus Research matches biotech companies with innovative sources of funding. We help both investors and biotechs realise the full potential of their respective investments.  More…
Investment/funding offered Investment/funding offered London-based firm providing series A & B financing and exit advice. Monitus Research provides early-stage financing to life science companies. We are specialists in the filed of life science assessment and valuation. We nurture our investments and offer strategic exit assistance. More…
Investment/funding offered Investment/funding offered MTIP - Bringing MedTech to Market. More…
Investment/funding offered Investment/funding offered MTIP - Bringing MedTech Innovations to Market. More…
Investment/funding requested Investment/funding requested Nanovi. Nanovi enhances precision in the treatment of cancer being key to improve treatment for hospitals and patients. BioXmark® is the world’s first liquid marker turning gel-like after injection and enhancing precision in radiotherapy. It has a disruptive potential. Multiple clinical studies are... More…
Investment/funding requested Investment/funding requested Seeking Series A Investment. We are currently seeking 5 million CHF for the development of our canine itch candidate. This will allow us to develop and select our final dosage form, manufacture drug supplies, and complete safety and field efficacy studies. More…
Investment/funding requested Investment/funding requested Nordic Life Science Days. Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days... More…
Investment/funding requested Investment/funding requested NovaHep Excecutive Summary. Company description: NovaHep, Gothenburg, Sweden, is a biotechnology company founded in 2005 as a spin-off from the Karolinska Institute with a unique, proprietary technology in the field of regenerative medicine. Vision: As a pioneer within its field, the company has a clear vision... More…
Investment/funding requested Investment/funding requested Invest in NovaHep AB. NovaHep AB is a Swedish regenerative medicine company with a unique technology for engineering a broad range of biocompatible tissues and organs. The company is developing personalized blood vessels using novel processes for tissue engineering. The unique technology turns donated allogeneic... More…
Partners for research cooperation needed Partners for research cooperation needed Natural Products and Extracts Experts in Pharma, Nutra, Cosmetics for QC, GMP, R and D, Environment/Cleantech. More…
Partners for research cooperation needed Partners for research cooperation needed Medicinal and Aromatic Plant Biotechnology. Phytopharma and Nutra/Cosmetic Ingredients market have high demand for high Quality Medicinal and Aromatic Plant raw material. Agriculture and wild resources are limited. Plant Biotechnology can offer new and sustainable strategies for manufacturing High Quality Natural Active Biomasses. Partners... More…
Investment/funding offered Investment/funding offered Corporate Venture Fund. More…
Investment/funding requested Investment/funding requested Alzheimer - a new blood-based diagnostic approach - "proof-of-concept" achieved - combined with proprietary omega 3 based intervention product (OTC). Pre Diagnostics is managed by a highly experienced international biotech team determined to develop and commercialize an effective biomarker/diagnostic test for early stages of Alzheimer’s disease. In addition, the Company aims at developing a proprietary intervention product (medical nutrition)... More…
Investment/funding requested Investment/funding requested Chlamydia virulence blocker. Chlamydia is the most common sexually transmitted infection with 100 million new cases per annum globally. These infections are associated with a large economic burden. The direct medical cost was estimated to $3B in the US (2009). Moreover, Chlamydia is the main cause of Pelvic Inflammatory... More…
Investment/funding requested Investment/funding requested Tuberculosis tolerance inhibitor. Tuberculosis (TB) is the most deadly infectious disease with 1,8 million deaths yearly. The current standard treatment for drug susceptible TB is mainly effective and cures 80-85% of the treated. However the treatment is long, 6-9 months, the drug dose burden is high and this combination gives... More…
Investment/funding requested Investment/funding requested Healthcare Associated Infections, VRE, MRSA, C. diff etc. Infections caused by Gram positive pathogens, HAI pathogens, like Enterococcus faecalis, Streptococcus aureus or Clostridium difficile resistant to Vancomycin can be effectively treated with Vancomycin and compounds from QureTech Bio. These small molecules are bactericidal in their own but most... More…
Investment/funding requested Investment/funding requested A-round in Q3/17. ReFlow raised a single digit million CHF amount in our 09/16 seed round. The ReFlow seed investors are leading private cardiovascular investors who have developed and exited several successful medical device companies such as CoreValve (sold to Medtronic in 2009 for $700M+) and CardiAQ (sold to... More…
Investment/funding requested Investment/funding requested A-round in Q3/17. ReFlow raised a single digit million CHF amount in our 09/16 seed round. The ReFlow seed investors are leading private cardiovascular investors who have developed and exited several successful medical device companies such as CoreValve (sold to Medtronic in 2009 for $700M+) and CardiAQ (sold to... More…
Outlicensing offered Outlicensing offered Sterile micro dosing and measuring technology. We offer our micro dispensing and measuring technology to be integrated in Biotech/Medtech devices. Liquid amounts from 1ul - 100ml and Viscosity from 1-10mPas. More…
Investment/funding requested Investment/funding requested Micro dosing technology. To build distribution channels for our finised products and setup cooperations with device Manufacturers, we are looking for buiness angels and supporting organizations with expertise in biotechnology research and upstream (or related areas). More…
Partner request / distributor needed Partner request / distributor needed biotech laboratory devices for research and upstream. For our Products: - FoamFighter - B-drop - Pressure monitor We are looking for distributors in Europe. More…
Manufacturing requested Manufacturing requested Sterile, single-use electrical devices. We are looking for manufacturing partners that can assemble, glue, weld plastic parts for medical or biotech applications, including electrical components. More…
Partners Request (Research) Partners Request (Research) Best kept secret in Appried R&D: RISE-Research Institutes of Sweden looking for industrial partners. RISE is the result of the merger of four Swedish RTOs forming RISE-Research Institutes of Sweden. With a 50-50 business model (50% of our turn-over in industrially financed R&D Projects) we are now growing our international business rapidly. RISE has some 2300 personnel of which 30% hold a PhD or... More…
Investment/funding requested Investment/funding requested The Cancer Liquid Biopsy Will Disrupt Healthcare by 2020 (Forbes). We offer products and services to accurately quantify circulating tumor DNA (ctDNA) in a liquid biopsy sample, such as a blood test, or in tissue samples. Our products (KROMA™, IBSAFE™, and ActionSEQ™) are based on proprietary innovations (patent-pending), allowing for cost-effective detection... More…
Investment/funding offered Investment/funding offered Investment in Switzerland and in Scandinavian countries. Seventure is investing in the whole of Europe. Our representative at the SSBBS conference, Eric de La Fortelle, is the point person for investments in these two geographies. More…
Investment/funding offered Investment/funding offered Investment at nutrition/health interface particularly microbiome biology (symbiotic relationship between microbes and human physiology). Seventure has over 600 M€ under management, and recently (Dec 2015) finalized the 160 M€ Health for Life Capital fund dedicated to innovative products in pharmaceuticals, diagnostics, devices and nutrition coming from new understanding of microbiome biology. We invest at all stages of company... More…
Investment/funding requested Investment/funding requested SimplicityBio SA - Round A. We are raising $5M to accelerate our internal out-licensing oncology pipeline, enabling us to consolidate the team to finalise and out-license 3 models (biomarker panels and rules to use them) by end 2018 in: leukaemia treatment resistance, lung cancer confirmatory diagnosis and breast cancer... More…
Outlicensing offered Outlicensing offered Exploring interest. We will be out-licensing validated biomarkers and models for leukaemia treatment resistance, lung cancer confirmatory diagnosis and breast cancer recurrence prediction by 2018. We are looking to meet out-licensees to present our work and understand your needs and requirements. More…
Investment/funding requested Investment/funding requested Series A Financing. SinSa Labs seeks EUR 10 MM in common equity financing, drawn down in three, well-defined tranches, to advance its lead compound through Phase I/IIa clinical trials: •EUR 3.3 MM to complete IND-enabling studies, to be completed Q4 2017; •EUR 3.3 MM for SAD/MAD studies in healthy volunteers, to be... More…
Outlicensing offered Outlicensing offered Ex-US Rights to B2088 for Treatment of Gram-negative Bacterial Infection. SinSa Labs seeks thorough strategic and marketing relationships to commercialize its deep pipeline of anti-infective assets. SinSa's lead compound, B2088, is uniquely effective against Gram-negative bacteria, and acts in a way which is very unlikely to provoke antibiotic resistance. SinSa will... More…
Investment/funding offered Investment/funding offered Codevelopment and cofinancing partnership offered for clinical-stage projects. We are present at this conference to meet potential partners, and will be pleased to discuss co-funding clinical trial opportunities during or after the conference. We are particularly prepared to chair or participate in the future Eurostars application within the area of drug development or... More…
Investment/funding offered Investment/funding offered Funding for Applied R&D Projects. The State Secretariat for Education, Research and Innovation SERI is the federal government's specialised agency for national and international matters concerning education, research and innovation policy. We support Swiss companies and academia in their international innovation efforts. Among... More…
Investment/funding offered Investment/funding offered EUREKA/Eurostars funding rules and procedures.. Advice is offered for putting up a EUREKA or Eurostars project or check the suitability of an existing project idea for one of these instruments. More…
Outlicensing offered Outlicensing offered Licensing opportunity for Alzheimer's disease. Stemedica International SA is the first company to receive FDA investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer’s disease. The company has completed... More…
Investment/funding requested Investment/funding requested Investment opportunity for $19 billion/year market. An effective treatment for Alzheimer’s disease represents a vast market opportunity. Currently there are no drugs on the market that provide a disease-modifying treatment for this devastating disease. The company plans to out-license its treatment to one or more large pharmaceutical partners... More…
Investment/funding requested Investment/funding requested Investement in Growth Stage MedTech Company. Stratpharma is a medical device company focused on specialty dermatology and wound care. Stratpharma is in the growth stage with 5 products on the market and selling in 40 countries. Stratpharma will issue their next round of equity during 2017 to fund new product development and further... More…
Investment/funding requested Investment/funding requested Innovative medical eHealth platform focusing on cutting health care costs in millions.. More…
Partner for EUREKA/Eurostars collaboration wanted Partner for EUREKA/Eurostars collaboration wanted Innovative medical eHealth platform focusing on cutting health care costs in millions.. Seeking medical research partners for our innovative product. The partner could be research institute or hospital or a big clinic with access of target patients for our company. We have had success in getting soft money in Denmark and now we want to apply for Eurostars/EUREKA. If the partner is... More…
Investment/funding offered Investment/funding offered Sunstone Capital. Sunstone is a leading independent venture capital firm based in Northern Europe. Sunstone has approx. USD 1 billion in funds under management, and invests in early-stage companies with global potential within the Technology and Life Science sectors. Main focus: Drug development, Medical device,... More…
Investment/funding offered Investment/funding offered Seeking early-stage investments. Sunstone Life Science Ventures invests in early-stage Life Science companies in the therapeutic, medical technology and diagnostics fields. Our geographical scope is Europe with particular emphasis on the Nordic countries, Switzerland and Germany. We typically make our initial investment in... More…
Investment/funding requested Investment/funding requested vc2vc - a partnering event promoting co-investments. March 8-9, 2017 in Stockholm. vc2vc is a SwedenBIO partnering event between investors with in the Life Science sector. The program will include organized partnering, a few presentations of distinguished speakers, dinner and ample time for networking. The meeting will provide you with a smooth way into investing in Life... More…
Outlicensing requested Outlicensing requested Support in Internationalization. Switzerland Global Enterprise has been commissioned by the Swiss government to gather the performance mandates of export, location and import promotion under one roof. Switzerland Global Enterprise provides support to Swiss SMEs who are interested in exporting and links companies, experts and... More…
Investment/funding requested Investment/funding requested Investment/funding requested. tech2ART A/S is a 6 years old company with a mission to be a leading global player in safe, stable, and secure pH, DO (dissolved oxygen) monitoring and control during incubation of cells. Our existing products and technologies are based on a patented, new, truly disruptive technology for... More…
Manufacturing offered Manufacturing offered Therapure Biomanufacturing. Including its history as a product development company, Therapure has over 20 years of experience developing and manufacturing pharmaceutical products from a variety of sources including mammalian cell culture, whole blood / plasma and primary cell culture. Our scientific, process development,... More…
Investment/funding requested Investment/funding requested Timesulin Dose Capture for drug delivery systems. Patients Pending LTD (PP) develops and sells low cost and simple to use medical devices that reduce the intrusion of chronic conditions in the daily lives of patients. With a background in software development and best known for co-creating Skype, our focus on simplicity allows patients to live... More…
Investment/funding requested Investment/funding requested Umeå Biotech Incubator. We are looking for investors for the companies in our incubator. We have both med tech companies on the way out with their first product and pharma companies mainly in pre clinocal phase.. More…
Manufacturing requested Manufacturing requested Bioactive scaffoldings for nerve/axonal regeneration. Please describe your co-operation profile according to the example headings mentioned below. Find examples of good co-operation profiles on www.b2match.eu/ssbbs2012/participants/14 or www.b2match.eu/go4cleantech/pages/profiles More…
Partners Request (Research) Partners Request (Research) Bioactive biomaterials and tissue engineered products. Research interest: - Biomaterials - Adipose stem cells - Nerve conduit scaffolds - Drug Delivery - Repair and regeneration of nervous system More…
Partner request / distributor needed Partner request / distributor needed Valuation and Licensing Search. Company Valuation:----------------------------The Company Valuation Reports include a thorough assessment of the company by experienced professionals with expertise in the relevant fields as well as the following elements:• summary of key risk parameters and strengths of the company• outline of... More…
Investment/funding requested Investment/funding requested Series B. Versantis seeks investments to initiate a Phase 2a in liver patients.. Versantis is developing breakthrough liver disease medicines addressing high unmet medical needs. Its lead candidate, VS-01, is the first drug for acute liver disease and can simultaneously address multiple organ failures. Owing to a granted orphan drug designation and a validated safety... More…
Partner for EUREKA/Eurostars collaboration wanted Partner for EUREKA/Eurostars collaboration wanted Therapeutic approaches in rare metabolic diseases. We are interested in collaborating in EUREKA/Eurostars projects in the area of metabolic disease, in particular to improve the care of hyperammonemic patients with Urea Cycle Disorders. More…
Investment/funding offered Investment/funding offered EUREKA, public funding for your innovative project. We can provide information on EUREKA funding for your research and innovation project. More…
Investment/funding offered Investment/funding offered Vinnova. More…
Investment/funding offered Investment/funding offered Wille Finance AG. We are a Family Office investing into Private Equity and Venture with a focus in ICT and life science. More…